Fitch:Nuclear Exit Continues Under Low Natural Gas/Energy Prices

NEW YORK--(BUSINESS WIRE)-- Exelon Corp.'s (EXC) announcement Thursday that it will retire the Clinton and Quad Cities nuclear facilities may precipitate other nuclear plant closures as the trend of nuclear shutdowns continues, according to Fitch Ratings.

The planned shutdowns highlight difficult operating conditions for merchant generators due in large measure to low natural gas and energy prices amid sluggish demand. Nuclear units are particularly vulnerable because of their high fixed operating and capital costs. Clinton will close on June 1, 2017 and Quad Cities on June 2018.

Both Quad Cities and Clinton have been cash flow negative for several years, and management had previously indicated closure was a strong possibility without a rebound in energy and capacity prices and the passage of legislation in Illinois that would reward low carbon-emitting power plants. The situation came to a head when Quad Cities did not clear the 2019/2020 PJM forward capacity auction and the potential Illinois legislation stalled. Although Clinton did clear the Midwest independent System Operator (MISO) capacity auction, the prices were inadequate. The two nuclear facilities (three plants) have a strong operating record and provide nearly 2,500 MW of carbon-free capacity.

Fitch considers several other plants at risk of early retirement including the Byron, Ginna, Nine Mile Point and Three Mile Island (TMI) nuclear facilities also owned by EXC. TMI did not clear the PJM capacity auction for the second consecutive year and only a portion of Byron's capacity cleared the auction. Byron is committed to operate through May 2020. Ginna and Nine Mile Point could be saved by a proposed clean energy mandate in New York that would include a credit paid to nuclear operators to help keep plants in operation.

EXC had previously announced plans to retire the Oyster Creek nuclear unit in 2019. Similarly, Entergy announced plans to close the Fitzpatrick and Pilgrim nuclear units in January 2017 and no later than June 2019, respectively.

Additional information is available on www.fitchratings.com.

The above article originally appeared as a post on the Fitch Wire credit market commentary page. The original article, which may include hyperlinks to companies and current ratings, can be accessed at www.fitchratings.com. All opinions expressed are those of Fitch Ratings.

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602006398/en/

Fitch Ratings
Robert Hornick, +1 212 908-0523
Senior Director
Corporate Finance
Fitch Ratings
33 Whitehall Street
New York, NY 10004
or
Kellie Geressy-Nilsen, +1 212 908-9123
Senior Analyst
Fitch Wire
or
Media Relations
Alyssa Castelli, +1-212-908-0540 (New York)
[email protected]

Source: Fitch Ratings

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• New Meme Coins for Late August: $BULLSKI Leads the Fresh Entries
• Crypto Presale Guide: What $BULLSKI’s Published Ladder Actually Fixes